sameAs
P161
Benfluorex and unexplained valvular heart disease: a case-control studyT-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases.Fenfluramine-like cardiovascular side-effects of benfluorex.Benfluorex withdrawal in France: Still be hiding somewhere in the world?Update on the roles of distal airways in asthma.Evaluation of quantitative PCR for early diagnosis of Pseudomonas aeruginosa infection in cystic fibrosis: a prospective cohort study.Transforming growth factor beta in normal human lung: preferential location in bronchial epithelial cells.Computed tomography of complications of lung transplantation.[Contraception, therapeutic abortion, and pulmonary arterial hypertension].[Treatments targeting distal airways in asthma: update on clinical studies].Education and self-management: a one-year randomized trial in stable adult asthmatic patients.CFTR transgene expression in primary DeltaF508 epithelial cell cultures from human nasal polyps following gene transfer with cationic phosphonolipids.Pulmonary hypertension associated with benfluorex exposure.Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?Highlighting the impact of cascade carrier testing in cystic fibrosis families.[Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?]À propos de l’expertise des dossiers benfluorex (Mediator® et génériques)Correspondance à propos de l’article : « Benfluorex (Mediator®) et atteintes valvulaires »Mitral and aortic valvular disease associated with benfluorex useBenfluorex (Mediator®), notre vigilance en questionHypertension artérielle pulmonaire du sujet âgé. La cohorte d’un centre régionalImprovement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapyCharacterisation of severe obliterative bronchiolitis in rheumatoid arthritisChronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomyDiagnostic et prise en charge de l’hypertension pulmonaire postembolique : le rôle du pneumologueQuantification of CFTR splice variants in adults with disseminated bronchiectasis, using the TaqMan fluorogenic detection system[Education of the adult asthmatic]Q56997139Accelerated obstructive pulmonary disease in HIV infected patients with bronchiectasisPREDICTIVE VALUE OF CYTOMEGALOVIRUS DNA DETECTION BY POLYMERASE CHAIN REACTION IN BLOOD AND BRONCHOALVEOLAR LAVAGE IN LUNG TRANSPLANT PATIENTS1Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic studyParticular phenotypic profile of blood lymphocytes during obliterative bronchiolitis syndrome following lung transplantationEmergence of inflammatory alveolar macrophages during rejection or infection after lung transplantationMediator 150 mgAlgorithme diagnostique. Comment je raisonne devant une HTAP ?
P50
Q21091138-54091DD2-FC6B-4503-821B-5467E15C5CB0Q33456341-D13B05F5-B9CC-45B1-979D-33D2CE1C2F29Q33721459-489A4B93-E613-44A5-A3E1-ED14259C994AQ34658157-B53F7554-2B87-4208-ADCC-B2E6EC3D7DD0Q35411550-B2709D35-3CCA-4A9E-A90A-36F516210692Q37801140-D6ADC1C5-E9E6-4C8B-8BCC-7D433E62491DQ40429062-C217A356-A382-4232-BF17-2A5877C86A5BQ41233801-7C2FF8F5-7F04-45E1-BC16-3BFBFA38AD8CQ41535477-DC33CC01-9543-4757-8629-CE8D357FFA02Q42928715-9334087D-04E5-4D51-A5A3-BCBE90D98E47Q43232443-0DD286AC-E602-47D8-86EF-1E91E04FD0B3Q43862988-3935D346-D7C1-46C6-9662-FB6D1E7FE963Q45873513-8C312E68-34B3-4728-A687-1622A2520B85Q46604185-72CC766F-3AB7-4E36-97FB-CD7E0B4325EBQ49615426-86BE340B-6955-4366-AE3B-6B8A715613D0Q50915884-FE73827B-F2F4-4CD9-B331-C0F8F3359C8BQ54016196-C9F5BC78-1AEE-44E1-AB94-F53461DC536CQ56997074-799E36E5-613F-417E-BFA1-1AF030834272Q56997080-4BE270CD-6087-487E-BB4C-F0ECA9F604CBQ56997086-0F0C4333-6333-41FD-BDA3-6CBE8B57BB57Q56997090-152CB95A-B8DC-4229-9F51-99320B1CB721Q56997099-E2F13DA0-8083-4F40-9AC2-1D6E9F06D541Q56997104-35C9EF5E-74AF-4E0B-8903-B74A121D4719Q56997111-03745C13-4204-40A8-B357-2C1B3D338CF7Q56997117-8D574A0C-0A83-4077-952B-E22763247149Q56997122-DCE3F44C-9B2B-4081-9747-EAF47E718373Q56997128-9AE55D59-F5A5-41CF-BAEF-1D096D354317Q56997133-F1B9F32B-5C92-47DF-B7C1-EB33E2B55D95Q56997139-52CCC3DC-B62A-427A-89EA-94BAE0F744FCQ56997144-A8CD354B-88C2-4415-AECE-76AFD0B5F45AQ56997148-4542FA27-A2CF-47A2-A374-E06181C131DDQ56997155-89970DD3-3E0E-464B-B3C5-D71BBE3F974FQ56997160-11E4B239-6A97-49AB-8CA1-66741A5E84B3Q56997165-DBA565B2-9C6B-4069-BA54-E8DC224CF395Q60034755-c3b9fdb8-431c-1111-e378-452375060990Q61895118-86B7AC91-EAE4-4BF0-9C8F-39CC3D21B560
P50
description
Frans arts
@nl
French physician
@en
French physician
@en-ca
French physician
@en-gb
Prantsusmaa arst
@et
dochtúir Francach
@ga
doctoriță franceză
@ro
dokter asal Perancis
@id
medico francese
@it
metgessa francesa
@ca
name
Irène Frachon
@ast
Irène Frachon
@br
Irène Frachon
@ca
Irène Frachon
@da
Irène Frachon
@en
Irène Frachon
@es
Irène Frachon
@fr
Irène Frachon
@hu
Irène Frachon
@it
Irène Frachon
@nb
type
label
Irène Frachon
@ast
Irène Frachon
@br
Irène Frachon
@ca
Irène Frachon
@da
Irène Frachon
@en
Irène Frachon
@es
Irène Frachon
@fr
Irène Frachon
@hu
Irène Frachon
@it
Irène Frachon
@nb
altLabel
Frachon I
@en
Frachon I.
@en
Frachon
@en
I Frachon
@en
I. Frachon
@en
Irene Frachon
@en
Irene Frachon
@es
Irene Frachon
@nl
Irène Allier
@fr
prefLabel
Irène Frachon
@ast
Irène Frachon
@br
Irène Frachon
@ca
Irène Frachon
@da
Irène Frachon
@en
Irène Frachon
@es
Irène Frachon
@fr
Irène Frachon
@hu
Irène Frachon
@it
Irène Frachon
@nb
P1038
P214
P244
P268
P269
P4285
P1412
P1477
Irène Allier
@fr
P1559
Irène Frachon
@fr
P21
P213
0000 0001 2297 0014
P214
P244
n2016051483